Header Logo

Connection

WILLIAM G WIERDA to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications WILLIAM G WIERDA has written about Antibodies, Monoclonal, Humanized.
WILLIAM G WIERDA
Connection Strength
1.171
Antibodies, Monoclonal, Humanized
  1. The use of obinutuzumab in chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2014 Jun; 12(6):395-7.
    View in: PubMed
    Score: 0.207
  2. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429.
    View in: PubMed
    Score: 0.084
  3. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020 04 18; 395(10232):1278-1291.
    View in: PubMed
    Score: 0.078
  4. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248.
    View in: PubMed
    Score: 0.067
  5. Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab. Hematol Oncol Stem Cell Ther. 2017 Sep; 10(3):151-154.
    View in: PubMed
    Score: 0.060
  6. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. Br J Haematol. 2015 Jul; 170(1):40-9.
    View in: PubMed
    Score: 0.055
  7. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. Clin Lymphoma Myeloma Leuk. 2015 Jul; 15(7):385-91.
    View in: PubMed
    Score: 0.054
  8. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011 Nov 10; 118(19):5126-9.
    View in: PubMed
    Score: 0.043
  9. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood. 2011 Aug 25; 118(8):2062-8.
    View in: PubMed
    Score: 0.042
  10. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood. 2011 Aug 25; 118(8):2085-93.
    View in: PubMed
    Score: 0.042
  11. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011 Jun 16; 117(24):6450-8.
    View in: PubMed
    Score: 0.042
  12. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer. 2011 Jan 01; 117(1):116-24.
    View in: PubMed
    Score: 0.040
  13. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 01; 28(10):1749-55.
    View in: PubMed
    Score: 0.039
  14. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma. 2007 Oct; 48(10):1931-9.
    View in: PubMed
    Score: 0.033
  15. Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol. 2005 Sep 10; 23(26):6325-32.
    View in: PubMed
    Score: 0.028
  16. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na?ve chronic lymphocytic leukemia. Leukemia. 2022 04; 36(4):1171-1175.
    View in: PubMed
    Score: 0.022
  17. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. J Geriatr Oncol. 2020 01; 11(1):19-23.
    View in: PubMed
    Score: 0.018
  18. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood. 2019 06 27; 133(26):2765-2775.
    View in: PubMed
    Score: 0.018
  19. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol. 2018 03; 93(3):371-374.
    View in: PubMed
    Score: 0.017
  20. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 03 09; 129(10):1275-1283.
    View in: PubMed
    Score: 0.015
  21. Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. Leuk Lymphoma. 2017 02; 58(2):348-356.
    View in: PubMed
    Score: 0.015
  22. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. Clin Cancer Res. 2016 05 15; 22(10):2359-67.
    View in: PubMed
    Score: 0.014
  23. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica. 2015 Aug; 100(8):e311-4.
    View in: PubMed
    Score: 0.014
  24. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer. 2014 Nov 15; 120(22):3494-501.
    View in: PubMed
    Score: 0.013
  25. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. J Clin Pharmacol. 2014 Jul; 54(7):818-27.
    View in: PubMed
    Score: 0.013
  26. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer. 2010 May 15; 116(10):2360-5.
    View in: PubMed
    Score: 0.010
  27. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10; 27(32):5425-30.
    View in: PubMed
    Score: 0.009
  28. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood. 2009 Jul 30; 114(5):957-64.
    View in: PubMed
    Score: 0.009
  29. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer. 2009 Jan 15; 115(2):373-80.
    View in: PubMed
    Score: 0.009
  30. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009 Feb 01; 27(4):504-10.
    View in: PubMed
    Score: 0.009
  31. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Eur J Haematol. 2008 Apr; 80(4):296-8.
    View in: PubMed
    Score: 0.008
  32. Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies. Cancer. 2007 Dec 01; 110(11):2478-83.
    View in: PubMed
    Score: 0.008
  33. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008 Feb 15; 111(4):1816-9.
    View in: PubMed
    Score: 0.008
  34. T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. Leuk Res. 2007 Jul; 31(7):939-45.
    View in: PubMed
    Score: 0.008
  35. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006 Jun 15; 106(12):2645-51.
    View in: PubMed
    Score: 0.007
  36. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003 Dec 15; 98(12):2657-63.
    View in: PubMed
    Score: 0.006
  37. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003 May 01; 101(9):3413-5.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.